Table 1.

Baseline characteristics of patients enrolled in this randomized trial compared by target hemoglobin level

CharacteristicTarget 9.5 to 11.5 g/dlTarget 13.5 to 14.5 g/dlP
n300296
Hemoglobin (g/dl)11.0 (10.8 to 11.1)11.0 (10.9 to 11.2)0.54
Epoetin dose (IU per week)6183 (5698 to 6667)7009 (6528 to 7490)0.02
Transferrin saturation (%)36.8 (34.9 to 38.8)35.8 (33.8, 37.7)0.44
Age49.4 (47.7 to 51.2)52.2 (50.4 to 53.9)0.03
Female sex (%)39.739.50.97
Race0.24
    white87.791.2
    black5.74.4
    Asian4.31.7
    other2.32.7
Dialysis duration (months)10.2 (9.6 to 10.8)10.0 (9.4 to 10.5)0.58
Body mass index (kg/m2)26.3 (25.7 to 26.9)26.5 (25.9 to 27.1)0.78
Country (%)
    Austria3.04.1
    Belgium3.34.7
    Canada32.027.7
    France3.02.7
    Germany11.012.5
    Greece2.31.4
    Hungary10.712.2
    Poland22.322.6
    Spain3.03.0
    United Kingdom9.39.1
Primary cause of renal disease0.54
    glomerulonephritis29.028.4
    diabetes16.718.9
    hypertension9.36.8
    polycystic kidney disease7.710.5
    Other/unknown37.335.5
Dialysis access (%)0.21
    fistula82.785.8
    graft5.06.1
    catheter12.38.11
Serum albumin (mg/dl)4.0 (3.9 to 4.0)4.0 (3.9 to 4.0)0.88
  • Data are reported either as percent or as means (95% confidence intervals). The chi-squared test and analysis of variance were used for between-target comparisons.